# Stacie Hudgens

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stacie-hudgens/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,154 |
| Field | Health Systems, Economic Evaluations, Quality of Life |
| h-index | 27 |
| i10-index | 46 |
| Last Known Institution | Health Outcomes Solutions (United States) |
| OpenAlex ID | https://openalex.org/A5084322798 |
| ORCID iD | 0000-0002-7350-1549 |
| Works | 171 |

## Researcher papers

- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Measuring the side effects of taxane therapy in oncology](https://scholariq.org/papers/measuring-the-side-effects-of-taxane-therapy-in-oncology/)
- [Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study](https://scholariq.org/papers/quality-of-life-in-patients-with-newly-diagnosed-chronic-phase-chronic-myeloid/)
- [Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial](https://scholariq.org/papers/lenvatinib-versus-sorafenib-for-first-line-treatment-of-unresectable/)
- [Atherosclerotic risk factor reduction in peripheral arterial disease](https://scholariq.org/papers/atherosclerotic-risk-factor-reduction-in-peripheral-arterial-disease/)
- [Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/effect-of-apalutamide-on-health-related-quality-of-life-in-patients-with-non/)
- [Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/quality-of-life-in-patients-with-recurrent-ovarian-cancer-treated-with-niraparib/)
- [Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials](https://scholariq.org/papers/effect-of-adalimumab-on-visual-functioning-in-patients-with-noninfectious/)
- [Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant](https://scholariq.org/papers/meaningful-change-in-depression-symptoms-assessed-with-the-patient-health/)
- [Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial](https://scholariq.org/papers/health-related-quality-of-life-in-patients-with-locally-advanced-or-metastatic/)

## Researcher topics

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)

## Researcher university

- [Health Outcomes Solutions (United States)](https://scholariq.org/institutions/health-outcomes-solutions-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.